erlotinib (CP 358,774)

11/01/2006 - "Developmental studies of either drug have failed to show synergistic effects when combined with cytotoxic drugs as the first line treatment in patients with advanced non-small cell lung cancer, but erlotinib has shown survival prolongation when compared with best supportive care in patients with recurrence. "
06/01/2012 - "However, two recent clinical case reports showed that erlotinib caused complete remission of acute myeloid leukaemia (AML)-M1 in patients who had both AML-M1 and non-small-cell lung cancer. "
09/01/2013 - "A randomized trial carried out by Shepherd et al. in patients with advanced or metastatic non-small-cell lung cancer showed statistically significant benefit of erlotinib over placebo in prolonging overall survival and progression-free survival. "
11/01/2014 - "Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for dacomitinib compared with erlotinib. "
03/01/2012 - "The purpose of this study was to evaluate the efficacy of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer (NSCLC). "

10/01/2013 - "Taken together, these data indicate that CH5164840 has potent antitumor activity and is highly effective in combination with erlotinib against NSCLC tumors with EGFR overexpression and mutations. "
01/01/2008 - "The most significant cases were two non-smokers women with bronchioloalveolar cancer, who remain in complete remission after erlotinib treatment. "
11/17/2015 - "We found that intermittent high-dose treatment with erlotinib induced apoptosis more potently and improved tumor shrinkage significantly than the established low doses. "
11/15/2015 - "When combined with the EGFR-targeted drug erlotinib, DLL-1 significantly improved progression-free survival by inducing robust tumor-specific T-cell immunity. "
10/01/2013 - "Erlotinib resistance led to delayed onset of tumor growth as well as prolonged overall survival of mice without changing tumor morphology. "

11/01/2013 - "We evaluated the efficacy of erlotinib plus GEM in patients with unresectable pancreatic cancer. "
04/01/2013 - "It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC). "
01/01/2014 - "Within the phase III study AIO-PK0104 281 patients with advanced pancreatic cancer received an erlotinib-based 1st-line regimen. "
07/01/2008 - "Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?"
06/01/2008 - "Only studies using erlotinib in pancreatic cancer patients were reviewed and analyzed. "

09/01/2006 - "The objective of this study was to determine the tolerability and efficacy of high-dose erlotinib administered on a weekly schedule to patients with advanced nonsmall cell lung cancer (NSCLC). "
11/17/2015 - "Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer."
08/20/2006 - "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21."
08/15/2014 - "In addition, moderate clinical efficacy of the EGFR-TKI, erlotinib, has been shown in lung cancer patients with the wild-type EGFR. "
01/01/2012 - "Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not been evaluated. "

10/01/2011 - "As seen in this patient, high CSF concentrations of erlotinib can be achieved by high-dose administration, and this finding suggests the efficacy of high-dose administration, especially to refractory CNS metastases of NSCLC patients."
10/01/2013 - "Finally, erlotinib is expected to be effective in the treatment of brain metastasis."
12/20/2009 - "Erlotinib may be effective on brain metastases in NSCLC patients and appears to be a possible new treatment option."
10/01/2011 - "We describe a Japanese woman with NSCLC and CNS metastases who was resistant to 75 mg daily erlotinib, but the metastases were improved by 150 mg daily erlotinib. "
03/01/2008 - "Two case reports are presented illustrating the efficacy of erlotinib in patients with recurrent brain metastases and parallel thoracic progression. "